Johnson & Johnson (NYSE:JNJ) Stock Position Lifted by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 35.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 292,600 shares of the company’s stock after purchasing an additional 76,000 shares during the quarter. Johnson & Johnson accounts for approximately 0.6% of Ilmarinen Mutual Pension Insurance Co’s holdings, making the stock its 12th largest position. Ilmarinen Mutual Pension Insurance Co’s holdings in Johnson & Johnson were worth $45,353,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Atlantic Private Wealth LLC bought a new position in Johnson & Johnson during the first quarter valued at about $32,000. GW&K Investment Management LLC bought a new position in Johnson & Johnson during the fourth quarter valued at about $35,000. Dark Forest Capital Management LP boosted its stake in Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after buying an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. bought a new position in Johnson & Johnson during the fourth quarter valued at about $42,000. Finally, Kepos Capital LP bought a new position in Johnson & Johnson during the fourth quarter valued at about $45,000. Institutional investors own 68.40% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. Stifel Nicolaus increased their price target on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Wells Fargo & Company decreased their price target on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a research report on Thursday, August 31st. HSBC initiated coverage on Johnson & Johnson in a research report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price target for the company. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday, August 21st. Finally, Barclays decreased their price target on Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating for the company in a research report on Friday, September 8th. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Hold” and an average price target of $170.65.

Johnson & Johnson Stock Up 0.6 %

JNJ opened at $163.64 on Wednesday. The business has a 50 day moving average price of $166.10 and a 200 day moving average price of $161.64. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The firm has a market cap of $425.30 billion, a P/E ratio of 33.13, a price-to-earnings-growth ratio of 3.47 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. During the same period in the previous year, the company earned $2.59 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.03 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were given a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.91%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 96.36%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.